Proteostasis Network Enhancement for CBS/PSP

Proteostasis Network Enhancement for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Proteostasis Network Enhancement for CBS/PSP</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>UPS Enhancement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Monomeric/oligomeric tau</td>
</tr>
<tr>
<td class="label">Clinical status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Key drugs</td>
<td>Bortezomib</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Key Interactions</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Immunosuppressants, antifungals</td>
</tr>
<tr>
<td class="label">Bortezomib</td>
<td>CYP3A4 substrates</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Limited drug interactions</td>
</tr>
<tr>
<td class="label">HDAC6 inhibitors</td>
<td>Limited data</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Ricolinostat</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">TUDCA</td>
<td>Phase 2</td>
</tr>
</table>

Proteostasis Network Enhancement for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Proteostasis Network Enhancement for CBS/PSP</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>UPS Enhancement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Monomeric/oligomeric tau</td>
</tr>
<tr>
<td class="label">Clinical status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Key drugs</td>
<td>Bortezomib</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Key Interactions</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Immunosuppressants, antifungals</td>
</tr>
<tr>
<td class="label">Bortezomib</td>
<td>CYP3A4 substrates</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Limited drug interactions</td>
</tr>
<tr>
<td class="label">HDAC6 inhibitors</td>
<td>Limited data</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Ricolinostat</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">TUDCA</td>
<td>Phase 2</td>
</tr>
</table>

The proteostasis network is a critical defense mechanism that maintains cellular protein homeostasis by coordinating protein folding, quality control, and degradation. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), the proteostasis network becomes overwhelmed by pathological tau aggregation, leading to progressive neurodegeneration. This page discusses therapeutic strategies to enhance proteostasis network function and restore protein quality control in these tauopathies.

The Proteostasis Network in CBS/PSP

CBS and PSP are characterized by the accumulation of hyperphosphorylated tau protein into neurofibrillary tangles and astrocytic plaques. The proteostasis network normally handles protein synthesis, folding, and degradation, but in tauopathies, this system becomes dysfunctional:

• Impaired protein degradation: Reduced activity of both the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway
• Chaperone dysfunction: Decreased expression and activity of heat shock proteins
• Aggregate formation: Sequestration of functional proteins into insoluble aggregates
• ER stress: Activation of the unfolded protein response (UPR)

Therapeutic Strategies

1. Ubiquitin-Proteasome System (UPS) Enhancement

The UPS is responsible for degrading most intracellular proteins, including phosphorylated tau. Enhancing UPS function can promote clearance of pathological tau species.

Proteasome Inhibitors

• Bortezomib: A reversible proteasome inhibitor that can paradoxically enhance proteasome activity in neurons through feedback mechanisms. Used in combination with other agents.
• Carfilzomib: An irreversible proteasome inhibitor with better blood-brain barrier penetration than bortezomib.

Mechanism

Clinical Considerations

• Monitor for peripheral neuropathy
• Dose adjustment for renal impairment
• Combination with autophagy inducers for synergistic effect

2. Autophagy-Lysosome Pathway Enhancement

The autophagy-lysosome pathway (ALP) is responsible for degrading aggregate-prone proteins and damaged organelles. Enhancing ALP function is a promising therapeutic strategy.

Pharmacological Inducers

mTOR Inhibitors

• Rapamycin (Sirolimus): Allosteric mTOR inhibitor that induces autophagy. Studies show neuroprotective effects in tauopathy models [1].
• Everolimus: Similar mechanism with better CNS penetration.

• Trehalose: Natural disaccharide that activates autophagy through mTOR-independent pathways [2]. Enhances clearance of tau aggregates in cellular and animal models.
• Lithium: GSK-3β inhibitor with autophagy-activating properties.

TFEB Activation

Transcription factor EB (TFEB) is the master regulator of lysosomal biogenesis and autophagy. TFEB activators include:

• Rapamycin: Promotes TFEB nuclear translocation
• Small molecule TFEB activators: In development for CNS disorders
• Protein phosphatase 2A (PP2A) activators: Enhance TFEB activity indirectly

3. Aggresome Targeting

Aggresomes are cytoplasmic inclusions that represent a cellular defense mechanism against toxic protein aggregates. While aggresome formation may be protective, targeting the aggresome machinery can enhance aggregate clearance.

HDAC6 Inhibitors

Histone deacetylase 6 (HDAC6) plays a crucial role in aggresome formation and autophagy. HDAC6 inhibitors include [3]:

• Tubastatin A: Selective HDAC6 inhibitor
• ACY-1215 (Ricolinostat): In clinical trials for various neurological conditions
• Tubastatin A analogs: In development with improved CNS penetration

Mechanism

4. Combination Approaches

Combining UPS enhancement with autophagy induction may provide synergistic benefits, as these pathways are complementary:

5. Heat Shock Protein Modulators

Heat shock proteins (HSPs) are molecular chaperones that facilitate protein folding and prevent aggregation. Modulating HSP activity can enhance proteostasis.

HSP70 Inducers

• Geldanamycin derivatives: 17-DMAG (Alvespimycin), 17-AAG (Tanespimycin)
• Geldanamycin: HSP90 inhibitor that induces HSP70 expression
• Small molecule HSP70 inducers: In development

Mechanism

Clinical Considerations

• HSP90 inhibitors can cause hepatotoxicity
• Careful monitoring required
• May affect cardiac function

6. ERAD/UPR Enhancement

The endoplasmic reticulum-associated degradation (ERAD) pathway and unfolded protein response (UPR) are critical for managing ER stress. Enhancing these pathways can protect neurons from tau-induced toxicity.

ER Stress Modulators

• TUDCA (Tauroursodeoxycholic acid): Chemical chaperone that reduces ER stress
• Sodium phenylbutyrate: UPR modulator in clinical use
• Salubrinal: Selective eIF2α dephosphorylation inhibitor

Protein Disulfide Isomerase (PDI) Modulators

PDI catalyzes disulfide bond formation in proteins. Modulators include:

• PDI inhibitors: For acute ER stress
• PDI inducers: For chronic proteostasis support

Patient-Specific Considerations

Genetic Variants

• MAPT mutations: Specific variants may respond differently to proteostasis modulators
• APOE status: APOE4 carriers may have impaired autophagy
• GBA variants: Associated with autophagy dysfunction in PSP

NET Assessment

Before initiating proteostasis therapy:

Drug Interactions

Research Pipeline

Clinical Trials

Emerging Therapies

• Gene therapy approaches: AAV-delivered chaperones
• Small molecule HSP70 inducers: Preclinical
• TFEB agonists: Preclinical
• Combination nanotherapy: Experimental

Cross-References

Related Mechanisms

• [Tau Aggregation Mechanisms](/mechanisms/tau-aggregation)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
• [ER Stress and UPR](/mechanisms/er-stress-upr)

Related Diseases

• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

See Also

• [Therapeutics Index](/therapeutics)
• [Clinical Trials Index](/clinical-trials)

References